Antibody Dermatology Drug Delivery Systems Drugs 
XTalks
AUGUST 14, 2024
The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) for the treatment of adult patients with the chronic skin condition prurigo nodularis. Monoclonal antibody therapy has been found to have fewer side effects when compared to immunosuppressant drugs.
Roots Analysis
MARCH 3, 2022
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].
Expert insights. Personalized for you.
98 
Let's personalize your content